HIGH POINT – vTv Therapeutics, a clinical-stage biopharmaceutical company that is developing a pipeline of clinical drug candidates for the treatment of Alzheimer’s disease, diabetes, and inflammatory disorders, has raised $2 million in equity and options, according to a recent SEC filing.
The High Point-based company did not list the number of investors, or indicate how it plans to use the funds. The firm has $8 million remaining to be sold to cap the round.
Rudy C. Howard signed the filing
Back in April 2018, the firm disclosed disappointing results from the clinical trial of an experimental Alzheimer’s medication. It announced that the Phase 3 clinical trial assessing the effects of the drug Azeliragon in patients with mild Alzheimer’s disease failed to achieve either co-primary endpoint.
The drug was intended to delay cognitive decline in patients. The company began the Phase 3 trial in 2015 after nearly 20 years of research and development.
VTV Therapeutics reports lower net loss after decreasing expenses
